←
Marco Bustamante539 posts
Marco Bustamante avatar

Marco Bustamante

@MarcoBus1967

Gastrointestinal Endoscopy Unit at @HospitalLaFe. Resarcher at @IISLaFe. Educational Twitter

◷ Joined July 2017▧ 157 Photos and videos
Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·18 Aug 2025

I share content on advanced endoscopy, clinical research and, sometimes, music. Posts in English and Spanish - Comparto contenidos sobre endoscopia avanzada, investigación clínica y, a veces, música. Publicaciones en inglés y español

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·May 22

As some of you may remember, this year I’m sharing my “CV of failures.” Previous score: 3 failures – 0 successes. Three months later, the balance has improved… modestly: ❌ 4 rejections (+1 unsuccessful grant) ✅ 1 acceptance (+1 paper published) Still time for a comeback ⚽️

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·Feb 22

Our final review on CADx for colonic lesions is out! Not a typical narrative review, this is a practical guide for anyone questioning AI’s true value in colonoscopy, with clear insights on how to interpret CADx study results. Worth a read 👉 doi.org/10.1016/j.bpg.2025.1…

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·Feb 9

Optical diagnosis of a juvenile polyp: 👉reddish or red-brown color 👉smooth to slightly granular surface with frequent erosions and adherent mucus 👉low pit density with broad/irregular crypt openings and prominent but regular capillaries. NICE, JNET and Kudo do not apply!

Post attachment
Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·2 Dec 2025

Recently, a French study challenged the rectal location as a risk factor for SMIC contradicting findings, among others, from the classic Australian group study (Burgess, Gastroenterol2017). Now, see the Australian response in Gut. Is this a major takedown? gut.bmj.com/content/early/20…

José C. Marín avatar
⟳ Marco Bustamante retweeted
José C. Marín@jocamaga1974·19 Nov 2025

Todo una oportunidad trabajar junto a @MarcoBus1967 👇🏻😊

SEED@SEEDendoscopia19 Nov 2025

📣 No podéis perderos el 4º caso del LIVE #SEED2025: cómo hacer un buen diagnóstico óptico y resección de una lesión en ciego de la mano de los expertos. El Dr. Jose Carlos Marín y el Dr Marco Bustamante nos enseñarán como plantear el diagnostico óptico y tratamiento de este tipo de lesiones @HospitalLaFe @SEEDendoscopia 📌 Jueves 20 de noviembre a las 09:00 horas en Auditorio 1 @PalcongresVLC ➕ congresoseed.es

Post attachmentPost attachment
Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·9 Sep 2025

Polyp from a patient with sessile serrated polyposis. Detected with TXI (A), delineated with acetic acid (B), injected for further delineation/resection (C,D), and resected with piecemeal cold EMR (E,F). Follow the @ESGE_news EMR guidelines for better practice!💪

Post attachment
Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·8 Sep 2025

This trial offers the first high-quality data to address this important clinical question 👋 🇪🇸🇪🇸🇪🇸We now look forward to the TRIASSIC study results, from The Netherlands, to be presented at UEGW 2025. 🤨

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·8 Sep 2025

And for your Hospital CEO .... ESD is cheaper 💰: he median total costs were €11,289.27 for TAMIS vs. €6,167.14 for ESD.

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·8 Sep 2025

And here are the results! 💣: ➡️ Patients: 34 TAMIS - 39 ESD ➡️ Differences in RLR: −6.7% (90% CI, −14.2 to 0.8) in the ITT analysis 👉 non-inferiority ➡️ Secondary outcomes (ESD vs TAMIS): TSR 100% vs 88.9%; R0 83.7% vs 59.3%; ER0 93% vs 66.7%; ECRR 83.7% vs 59.3% 👉ESD better

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·8 Sep 2025

What do these secondary outcomes mean?: 👉 ER0: complete resection with tumor-free margins regardless of the distance (you know that a 1 mm margin is arbitrary 👏) 👉 CRR: R0 + no high-risk features if adenocarcinoma 👉 ECRR: ER0 + no high-risk features if adenocarcinoma

Marco Bustamante avatar
Marco Bustamante@MarcoBus1967·8 Sep 2025

1⃣Main outcome: rate of local recurrence (RLR) at 12 months pos-procedure. 2⃣Secondary outcomes: technical success rate (TSR); R0 resection rate (R0); expanded R0 (ER0); curative resection rate (CRR); expanded curative resection rate (ECRR).